GW Pharmaceuticals plc Equity-NMS: GWPH

Healthcare

Drug Manufacturers - General

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$218.96

5Y :

72.33%

What is the share price of GW Pharmaceuticals plc today?

GW Pharmaceuticals plc (GWPH) share price as of July 3, 2025, is $218.96. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of GW Pharmaceuticals plc?

Yes, Indian Investors can invest in the GW Pharmaceuticals plc (GWPH) Share by opening an international trading account with Angel One.

How can I purchase GW Pharmaceuticals plc shares in India?

Purchasing GW Pharmaceuticals plc (GWPH) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying GW Pharmaceuticals plc (GWPH) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of GW Pharmaceuticals plc?

Yes, you can purchase fractional shares of GW Pharmaceuticals plc (GWPH) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of GW Pharmaceuticals plc?

The market capitalization of GW Pharmaceuticals plc on July 3, 2025, is $0.

In which sector GW Pharmaceuticals plc belongs?

GW Pharmaceuticals plc operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

What documents are required to invest in GW Pharmaceuticals plc stocks?

In order to invest in GW Pharmaceuticals plc (GWPH) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.